RaajitRampalMD

PubMed

• 14 citations
  Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
  Naveen Pemmaraju, Prithviraj Bose, Raajit Rampal, Aaron T Gerds, Angela Fleischman
  Leukemia & Lymphoma. 2023-06-01
• 54 citations
  Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.
  Fabio P.S. Santos, Bartlomiej Getta, Lucia Masarova, Christopher Famulare, Jessica Schulman
  Leukemia. 2020-03-01
• 310 citations
  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
  Raajit K. Rampal, Fatima Al-Shahrour, Omar Abdel-Wahab, Jay P. Patel, Jean-Philippe Brunel
  Blood. 2014-05-29

Journal Articles

• Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms  
  Robert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature
• Genetic and Epigenetic Evolution as a Contributor to WT1-Mutant Leukemogenesis  
  Raajit Rampal, Ross L Levine, Benjamin H Durham, Blood
• Jak2V617F and Dnmt3a Loss Cooperate to Induce Myelofibrosis Through Activated Enhancer-Driven Inflammation  
  Raajit Rampal, MD, Blood

Abstracts/Posters

• Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms
  Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells
  Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin
  Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
  Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Landscape of TP53 Mutations in MPN
  Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Gr...
  Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis
  Rajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 11...
  Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms
  Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic Impact of Activating Mutations of the NRAS/KRAS Genes in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all